Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs FENC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FENC Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

FENC Overall Winner 6-Pillar Tally: DMAC 0 – 5 FENC (1 Tie) Matrix Metrics: DMAC 2 – 8 FENC

As of Nov 16, 2026, Fennec Pharmaceuticals Inc. (FENC) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas FENC carries 44.2/100 (HOLD) at $12.00 (11.2x Forward P/E, 5.6% operating margin).

  • Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. FENC 44.2/100 HOLD), FENC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.6% vs. 0.0% operating margin) and revenue trajectory (+57.3% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs FENC
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
FENC NASDAQ Head-to-Head Winner
Fennec Pharmaceuticals Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$12.00
+3.27% 1D
Market Cap $405.7M
TTM Revenue $66M
Forward P/E 11.2x
Beta / 30D Vol 1.71β · 69% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 15.0 Fund 49.0 Flow 74.0 Mom 74.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 66
RSI-14: 66.2 · SMA20: $10.59 · SMA50: $10.64

6-Pillar Scorecard Institutional Category Breakdown (DMAC 0 – 5 FENC)

Columns: Metric · DMAC · FENC
1. Valuation Multiples FENC
Forward P/E N/M 11.2x
Trailing P/E N/M 12.6x
PEG Ratio N/M 1.47x
EV / Revenue N/M 6.1x
2. Growth & Scale FENC
Revenue Growth (YoY) +0.0% +57.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $66M
Market Cap $503.1M $405.7M
3. Profitability & Quality FENC
Gross Margin N/A 94.1%
Operating Margin 0.0% 5.6%
Net Profit Margin 0.0% 3.0%
Return on Equity (ROE) -114.6% 9.1%
4. Balance Sheet & Cash Flow FENC
Cash Generation (TTM) -$32M -$2.0M
Cash Flow Margin N/A -3.1%
Net Cash / Leverage $4.9M Net Cash $1.40 Book/Sh · 9.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FENC
Options Structure Phase SURGE BREAKOUT
Current IV / %ile 106.3% (14th %ile) 216.9% (24th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (2) vs FENC (8)
Institutional Metric DMAC FENC Criterion Row Edge
Market Capitalization
Scale
$503.1M $405.7M Larger Scale DMAC
Trailing P/E Ratio
Valuation
N/M 12.6x Lower Multiple FENC
Forward P/E Ratio
Valuation
N/M 11.2x Lower Multiple FENC
Revenue Growth (YoY)
Growth
+0.0% +57.3% Higher Growth FENC
Operating Margin (TTM)
Profitability
0.0% 5.6% Higher Margin FENC
Net Profit Margin
Profitability
0.0% 3.0% Higher Margin FENC
Return on Equity (ROE)
Capital Efficiency
-114.6% 9.1% Higher ROE FENC
52-Week Range Position
Momentum
55% ($5–$11) 84% ($6–$13) Stronger Trend FENC
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 1.71β · 69% Vol Lower Realized Risk FENC
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
N/A $66M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 94.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.47x PEG · 6.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$2.0M ($1.40 Book/Sh · 9.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FENC +9.08 pp
DMAC: +11.16% · FENC: +20.24%
3M Horizon DMAC +26.21 pp
DMAC: +27.31% · FENC: +1.1%
6M Horizon DMAC +23.15 pp
DMAC: +48.15% · FENC: +25.0%
1Y Horizon FENC +0.79 pp
DMAC: +55.26% · FENC: +56.05%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue FENC Revenue DMAC Op. Margin FENC Op. Margin Margin Leader
FY2018 $0M N/A -1352.2% N/A DMAC
FY2020 N/A $0M N/A -10520.6% FENC
FY2022 N/A $0M N/A -1471.6% FENC
FY2023 N/A $20M N/A -60.1% FENC
FY2024 N/A $50M N/A 5.4% FENC
FY2025 N/A $40M N/A -14.1% FENC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FENC BREAKOUT
98d in phase · OBV ACCUMULATION
Current IV 216.9%
IV Percentile 24th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact FENC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FENC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $405.7M market capitalization and 5.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs FENC Key Questions & Quantitative Answers

As of Nov 16, 2026, Fennec Pharmaceuticals Inc. (FENC) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas FENC carries 44.2/100 (HOLD) at $12.00 (11.2x Forward P/E, 5.6% operating margin). Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. FENC 44.2/100 HOLD), FENC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.6% vs. 0.0% operating margin) and revenue trajectory (+57.3% vs. +0.0% YoY).

FENC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FENC at +57.3% YoY revenue growth and +0.0% YoY earnings growth on $66M TTM revenue (94.1% gross margin, 5.6% operating margin). Across the 6-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while FENC shifted +100.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FENC.

FENC screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FENC trades at 11.2x Forward P/E, 12.6x Trailing P/E, 1.47x PEG, and 6.1x EV/Revenue (-3.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus FENC (9.1% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, FENC carries 216.9% implied volatility (24th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.